Abbott Laboratories Puts Former Solvay SA Flu-Vaccine Business Up for Sale; Could be Worth $619 Million

WSJ -- Abbott Laboratories is seeking a buyer for the flu-vaccine business it picked up in its recent purchase of Solvay SA's pharmaceutical unit, in a deal people familiar with the matter said could be worth €500 million ($619 million).